Recently, a study revealed that somatic mutation frequencies of FOXA1, ZNF292 and CHD1 in Chinese patients were remarkedly higher than those of Western cohorts by whole-genome, whole-transcriptome and DNA methylation data of 208 pairs of tumor tissues and matched healthy control tissues from patients with primary prostate cancer [51]. This evidence concerns the gene ZNF292 and prostate carcinoma.